← All businessesLogistics, Transport & Distribution / Medical & Pharma Supplies / Pharmaceutical wholesale
Short-Line Pharmaceutical Wholesaler In Manchester
Manchester, Greater Manchester, North WestIdentity protected
Available
About this business
Short-line pharmaceutical wholesaler in Manchester supplying generic medicines, branded lines and pharmacy sundries to independent community pharmacies across the North West. It leases a warehouse on an industrial estate and employs 8 people in buying, picking and dispatch. Sales have increased in each year since 2021, from £3.44m to £4.85m. EBITDA has risen more slowly, to £486k, so margins have narrowed as the business has pursued volume, which is common in medicines wholesale. A buyer who can improve purchasing terms could convert more of that growth into profit.
Key investment highlights
- Turnover up from £3.44m to £4.85m since 2021
- Sells to independent pharmacies in the North West
- Leased warehouse on a Manchester estate
- EBITDA of £486k
Reason for sale
The owner now runs a pharmacy chain and wants to sell the wholesale arm to avoid competing with its customers.
Nothing flagged on the two questions buyers ask first
No flagRevenue going backwards and one client being too much of it are the two things that end most deals in due diligence. Both are shown here up front, from the figures the seller supplied.
- Revenue directionNo flag
Turnover rose +5.8% in 2026.
- 2021: baseline
- 2022 (+6.3%)
- 2023 (+8.4%)
- 2024 (+5.2%)
- 2025 (+10.1%)
- 2026 (+5.8%)
6 years of turnover, 2021 to 2026, as supplied by the seller.
- Client concentrationNot stated
The seller has not declared what share of revenue the largest clients represent.
No declaration supplied. Client concentration cannot be derived from accounts.
EBITDA margin narrowed from 11.9% in 2021 to 10.0% in 2026.
These are observations from the supplied figures, not a view on whether this business is worth buying. Nothing here predicts an outcome.
Computing valuation...
What happens next
Submit an enquiry to the seller. Once they approve it, you sign a non-disclosure agreement and gain access to the information memorandum, the financials and a secure deal room with the seller.